Abiopharma

News list

Poseida Therapeutics (PSTX)

Event
Aug. 03, 2022, 11:36 UTC

(19% Negative) Poseida Therapeutics, Inc. (PSTX) Announces Delay in million Trials for multiple myeloma Due to Regulatory Process, Manufacturing Considerations, Efficacy Assessment

Full text

News bot Oct. 2, 2025, 5:29 p.m.

📋 Poseida Therapeutics, Inc. (PSTX) - Clinical Trial Update

Filing Date: 2022-08-03

Accepted: 2022-08-03 07:36:12

Event Type: Clinical Trial Update

Event Details:

Poseida Therapeutics (PSTX) Announces Clinical Trial Update Poseida Therapeutics (PSTX) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: million, targets
Diseases/Conditions: multiple myeloma
Update Type: Trial Timeline Adjustment
Primary Factors: Regulatory Process
Collaboration: ET SAN DIEGO
- anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the fact that the collaboration agreement may not become effective based on HSR Act clearance, or the effectiveness may be substantially delayed, or may be terminated early, the fact that the Company will have limited control over the efforts and resources that Roche devotes to advancing development programs under the collaboration agreement and Poseida may not receive the potential fees and payments under the collaboration agreement or fully realize the benefits of the collaboration, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future preclinical and clinical results could be inconsistent with results observed to date, and the other risks described in Poseida’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. ### Investor contact: Alex Lobo Stern Investor Relations Alex.lobo@sternir.com Media contact: Sarah Thailing Senior Director, Corporate Communications and IR Poseida Therapeutics, Inc. 858-605-3717
- expected in 2023

🔬 Clinical Development Pipeline (Poseida Therapeutics, Inc.):

Product	Type	Development Stage	Therapeutic Area	Source
P-CD19CD20-ALLO1	BIOLOGICAL	Phase PHASE1	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	ClinicalTrials.gov
Rimiducid	DRUG	Phase PHASE1	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Poseida Therapeutics
CIK: 0001661460
Ticker Symbol: PSTX
Period End Date: 2022-07-30
Document Type: 8-K